{"id":"67cu-sar-bispsma","phase":"phase_1","safety":{"commonSideEffects":[]},"status":"active","trials":["NCT04868604"],"aliases":[],"patents":[],"pricing":[],"timeline":[],"aiSummary":"PSMA-targeting radioligand Used for Prostate cancer.","brandName":"67Cu-SAR-bisPSMA","companyId":"clarity-pharmaceuticals-ltd","mechanism":{"_ai_source":"groq-llama-8b","explanation":"67Cu-SAR-bisPSMA is a radioligand that targets prostate-specific membrane antigen (PSMA) for the treatment of prostate cancer.","oneSentence":"PSMA-targeting radioligand","_ai_confidence":"medium"},"commercial":null,"companyName":"Clarity Pharmaceuticals Ltd","competitors":[],"genericName":"67Cu-SAR-bisPSMA","indications":{"approved":[{"name":"Prostate cancer"}]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}